TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
5.57
-0.08 (-1.42%)
Apr 25, 2025, 2:47 PM EDT - Market open

Company Description

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics for improving outcomes for patients with difficult-to-treat liver and pancreatic cancers.

It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

The company also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.

It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.

TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

TriSalus Life Sciences, Inc.
TriSalus Life Sciences logo
Country United States
Founded 2010
Industry Medical Devices
Sector Healthcare
Employees 112
CEO Mary Szela

Contact Details

Address:
6272 West 91st Avenue
Westminster, Colorado 80031
United States
Phone (888) 321-5212
Website trisaluslifesci.com

Stock Details

Ticker Symbol TLSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001826667
CUSIP Number 89680M101
ISIN Number US89680M1018
Employer ID 85-3009869
SIC Code 3841

Key Executives

Name Position
Mary T. Szela B.S.N., M.B.A. Chief Executive Officer, President and Director
Sean Edward Murphy Chief Manufacturing, Strategy and Business Development Officer and Director
Lori Ann Santamaria Vice President of Operations
Jennifer L. Stevens J.D. Chief Regulatory Officer
Dr. Richard B. Marshak M.B.A., MBA, VMD Chief Commercial Officer
Jodi Devlin Chief of Clinical Strategy and Operations
Dr. Bryan F. Cox Ph.D. Chief of Research

Latest SEC Filings

Date Type Title
Apr 23, 2025 8-K Current Report
Apr 17, 2025 8-K Current Report
Apr 15, 2025 10-K Annual Report
Mar 28, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 27, 2025 8-K Current Report
Feb 25, 2025 8-K Current Report
Feb 19, 2025 8-K Current Report
Feb 3, 2025 8-K Current Report
Jan 31, 2025 8-K Current Report
Jan 23, 2025 8-K Current Report